Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to 78.41%.

  • Arcturus Therapeutics Holdings' EBITDA Margin fell 618400.0% to 78.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 68.35%, marking a year-over-year decrease of 292900.0%. This contributed to the annual value of 53.14% for FY2024, which is 353200.0% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported EBITDA Margin of 78.41% as of Q3 2025, which was down 618400.0% from 32.44% recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' EBITDA Margin ranged from a high of 73.21% in Q4 2022 and a low of 2727.69% during Q2 2021
  • Moreover, its 5-year median value for EBITDA Margin was 78.41% (2025), whereas its average is 549.04%.
  • In the last 5 years, Arcturus Therapeutics Holdings' EBITDA Margin plummeted by -22857000bps in 2021 and then surged by 26481000bps in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' EBITDA Margin (Quarter) stood at 667.29% in 2021, then soared by 111bps to 73.21% in 2022, then tumbled by -152bps to 37.94% in 2023, then crashed by -247bps to 131.8% in 2024, then soared by 41bps to 78.41% in 2025.
  • Its last three reported values are 78.41% in Q3 2025, 32.44% for Q2 2025, and 47.91% during Q1 2025.